Michel Hantzperg

ICTA

ICTA is an international privately-owned CRO with 37 years of experience in clinical R&D, pharmaco-epidemiology and Early and Compassionate programs for APIs, cell therapies, diagnostics and medical devices. ICTA's international operations in Western/Eastern Europe and the USA provide full clinical research or "a la carte" services in traditional and adaptive clinical trials from Early Phase to Late Phase across a broad range of therapeutic areas. Our active interaction with a high-level international academic network, our adaptive management supported by a powerful secured information system (I-SIT platform) are hallmarks which made of ICTA one of the first few CROs able to design and successfully conduct adaptive and Bayesian clinical trials including seamless studies. Today ICTA's consulting unit provides the pharmaceutical, medical device and biotech industries with strategic advice at every stage of your clinical developments.